Vicore Pharma Holding AB at ABGSC Life Summit Transcript
Welcome back. The next company to present is Vicore, and I'm pleased to be joined virtually by their CFO, Hans Jeppsson. Vicore is a Swedish company in mid-stage clinical development with a lead asset C21 that recently reported some promising data in idiopathic pulmonary fibrosis. I'll hand the word over to Hans to tell you more about it.
Thanks a lot for that. So my name is Hans Jeppsson, I'm the CFO of Vicore. So Vicore is developing a new class of drugs, AT2 receptor agonist, which we think, if the data continue to hold through, could really lay a new foundation in medicine.
So next slide, please. Next slide. So the team and the Board. I think we have made three additions last year and build a complete management team with the addition of Jessica Shull, Head of Digital Therapeutics and leading those efforts; and Mikael NygÃ¥rd, Vice President, Business Development; and Ãsa Magnusson at the bottom right in leading our commercial efforts
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |